Standardisation and improvement of generic pre-analytical tools and procedures for in-vitro diagnostics

ABOUT SPIDIA AND SPIDIA4P

SPIDIA was a 4.5-years project funded by the European Union FP7 programme. It brought together 16 leading academic institutions, international organisations and life sciences companies, coordinated by QIAGEN GmbH. The project tackled the standardisation and improvement of pre-analytical procedures for in-vitro diagnostics. Various new pre-analytical technologies were developed. Within the CEN/Technical Committee 140 for “In vitro medical devices”, SPIDIA’s results enabled to develop and introduce the first 9 CEN Technical Specifications (CEN/TS) for pre-analytical workflows in Europe.

The SPIDIA4P project builds on SPIDIA’s results and is funded by the European Union’s Horizon 2020 research and innovation programme. The consortium of 19 highly experienced partners from private industry including SMEs, public institutions and one European Standards Organisation is again coordinated by QIAGEN GmbH. It plans to initiate, develop and implement a comprehensive portfolio of an additional 14 pan-European pre-analytical CEN/TS and ISO/IS documents as well as external quality assessment schemes (EQAs), addressing the important pre-analytical workflows applied to personalised medicine.

Get the latest information about the SPIDIA4P project, the work progress and the project partners in the first edition of our Newsletter - hot off the press!

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

On September 13, 2017, Dr. Uwe Oelmüller, QIAGEN, project-coordinator of SPIDIA and SPIDIA4P, was honoured for his comprehensive merits on pre-analytical standardisation in the EU – during the Global Biobank Week in Stockholm he was awarded the “DIN Golden Needle”!

The SPIDIA project has received funding under the Seventh Research Framework Programme of the European Union, FP7-HEALTH-2007-1.2.5, under grant agreement no. 222916.
The SPIDIA4P project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 733112.